Amylyx Pharmaceuticals (AMLX) Valuation Check After AMX0318 Rare Disease Pipeline Update

Simply Wall St.01-12

Amylyx Pharmaceuticals (AMLX) drew fresh investor attention after announcing AMX0318, a long-acting GLP-1 receptor antagonist, as a new development candidate for post-bariatric hypoglycemia and other ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602543356?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-01-12 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602543356","market":"nz","top_or_hot":-1,"title":"Amylyx Pharmaceuticals (AMLX) Valuation Check After AMX0318 Rare Disease Pipeline Update","media":"Simply Wall St.","content":"<div>\n<p>Amylyx Pharmaceuticals (AMLX) drew fresh investor attention after announcing AMX0318, a long-acting GLP-1 receptor antagonist, as a new development candidate for post-bariatric hypoglycemia and other ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-valuation-check-after-amx0318-ra\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amylyx Pharmaceuticals (AMLX) Valuation Check After AMX0318 Rare Disease Pipeline Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmylyx Pharmaceuticals (AMLX) Valuation Check After AMX0318 Rare Disease Pipeline Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-12 19:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-valuation-check-after-amx0318-ra><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amylyx Pharmaceuticals (AMLX) drew fresh investor attention after announcing AMX0318, a long-acting GLP-1 receptor antagonist, as a new development candidate for post-bariatric hypoglycemia and other ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-valuation-check-after-amx0318-ra\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMLX","symbol_name":"Amylyx Pharmaceuticals","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-valuation-check-after-amx0318-ra","article_id":"2602543356","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-valuation-check-after-amx0318-ra","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602543356","pubTimestamp":1768216545,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Amylyx Pharmaceuticals (AMLX) drew fresh investor attention after announcing AMX0318, a long-acting GLP-1 receptor antagonist, as a new development candidate for post-bariatric hypoglycemia and other rare diseases.\nSee our latest analysis for Amylyx Pharmaceuticals.\nThe AMX0318 announcement comes after a mixed stretch for the stock, with a 7-day share price return of 7.2% and a 30-day share price decline of 6.8%. The 1-year total shareholder return of about 3x suggests earlier momentum that...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMLX":"Amylyx Pharmaceuticals","BK4007":"制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"AMX0318罕见病管道更新后Amylyx Pharmaceuticals(AMLX)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"AMLX":1},"content_text":"Amylyx Pharmaceuticals (AMLX) drew fresh investor attention after announcing AMX0318, a long-acting GLP-1 receptor antagonist, as a new development candidate for post-bariatric hypoglycemia and other rare diseases. See our latest analysis for Amylyx Pharmaceuticals. The AMX0318 announcement comes after a mixed stretch for the stock, with a 7-day share price return of 7.2% and a 30-day share price decline of 6.8%. The 1-year total shareholder return of about 3x suggests earlier momentum that has cooled more recently. If the GLP 1 story at Amylyx has caught your eye, it may be a good moment to see what else is happening across healthcare stocks. With the shares at about US$12.21 and screens flagging a possible intrinsic discount, plus a value score of 4, you have to ask: is Amylyx still underappreciated, or is the market already baking in future growth? AdvertisementPrice to Book of 4x: Is it justified? On a P/B of about 4x, Amylyx trades close to the peer average of 4.4x, even though its shares last closed at roughly US$12.21. P/B compares the market value of the company to its accounting book value, which can be a common yardstick for unprofitable pharmaceutical names that are still investing heavily in research. For Amylyx, this frames what investors are currently paying relative to the net assets on its balance sheet. Statements flag the stock as good value versus direct peers at 4.4x, yet expensive versus the broader US pharmaceuticals group at 2.6x. That contrast suggests the market is pricing Amylyx more like its closer peer set rather than the wider industry. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 4x (ABOUT RIGHT) However, you still have to weigh clinical and execution risk around multiple late stage trials, alongside ongoing net losses of about US$149.3 million. Find out about the key risks to this Amylyx Pharmaceuticals narrative. Another View on Value Price to book paints Amylyx as roughly in line with close peers, but our DCF model points in a very different direction. With shares at about US$12.21 and our fair value estimate at US$52.44, the model suggests a very large potential gap. Is this a genuine opening or simply model risk showing through? Look into how the SWS DCF model arrives at its fair value. AMLX Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Amylyx Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 882 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Amylyx Pharmaceuticals Narrative If you see the numbers differently or prefer to test your own assumptions, you can build a fresh Amylyx view in minutes with Do it your way. A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision. Ready for more investment ideas? If Amylyx has sparked your curiosity, do not stop here. The market is full of other angles and you could miss some compelling setups.  Target potential value gaps by scanning these 882 undervalued stocks based on cash flows where prices and cash flow expectations can look out of sync. Spot early movers in next generation automation and data analysis through these 28 AI penny stocks before they sit on every headline. Lock onto income focused names using these 12 dividend stocks with yields > 3% so yield is front and center in your watchlist.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602543356","isCrawlerRequest":true}